Open AccessClinical remission of an inoperable malignant insulinoma by the combination treatment with octreotide and everolimus
Author(s) -
Akahori Hiroshi
Publication year - 2019
Publication title -
journal of general and family medicine
Language(s) - English
Resource type - Journals
ISSN - 2189-7948
DOI - 10.1002/jgf2.235
Subject(s) - medicine , everolimus , octreotide , insulinoma , somatostatin , somatostatin receptor , neuroendocrine tumors , discovery and development of mtor inhibitors , hypoglycemia , gastroenterology , oncology , pi3k/akt/mtor pathway , pancreas , insulin , apoptosis , biochemistry , chemistry
We report a 52‐year‐old woman with inoperable malignant insulinoma with multiple liver metastases. Histological examination of biopsy specimens from the pancreatic and hepatic lesions revealed pancreatic neuroendocrine tumor ( pNET ), G2. The tumor cells were positive for somatostatin receptor ( SSTR ) 2, 5, and the mammalian target of rapamycin ( mTOR ). Monthly intramuscular administration of octreotide LAR and once‐daily oral administration of everolimus combination treatment markedly reduced the sizes of liver metastases, and hypoglycemia was well controlled. Combination treatment with somatostatin analog and mTOR inhibitor may be another effective approach in inoperable metastatic malignant insulinoma.